Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.26−0.03 (-0.20%)
Close on Nov 18, 2026Market cap $82.16MP/E 3.3Yield –
Rallybio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Rallybio's revenue for the twelve months ending Sep 30, 2026 was $434.00K, down 35.6% year over year. For fiscal 2025 it was $858.00K, up 34.9% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $858.00K | +34.9% |
| FY2024 | Dec 31, 2024 | $636.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0 | -100.0% |
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $212.00K | 0.0% |
| Q4 FY2025 | Dec 31, 2025 | $222.00K | +484.2% |
| Q3 FY2025 | Sep 30, 2025 | $212.00K | -29.1% |
| Q2 FY2025 | Jun 30, 2025 | $212.00K | -29.1% |
| Q1 FY2025 | Mar 31, 2025 | $212.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $38.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $299.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $299.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?